Hormonal
Preserving or recovering beta-cell functional mass is the critical therapeutic strategy for preventing and managing type 2 diabetes, primarily achieved by reducing beta-cell workload through lifestyle modification and weight loss.
Focus on reducing the demand on your pancreas. Since human beta-cells have limited ability to regenerate, the best way to keep them working is to lower the workload. This means prioritizing lifestyle changes and weight loss to improve insulin sensitivity, thereby reducing the strain on your beta-cells and preserving their function.
Since beta-cell regenerative capacity appears somewhat limited in humans, reducing beta-cell workload appears to be the most effective way to preserve beta-cell functional mass to date, underpinning the importance of lifestyle modification and weight loss for the treatment and prevention of T2DM.
Why this rating
Based on a comprehensive review of multiple clinical studies (UKPDS, ADOPT, etc.) and histological analyses.
Source
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Yoshifumi Saisho · World Journal of Diabetes · 2015
DOI 10.4239/wjd.v6.i1.109
More from this paper
- Beta-cell dysfunction and loss of functional mass are present at the time of Type 2 Diabetes diagnosis and progressively decline by approximately 5% annually, independent of disease duration.Strong
- Ethnicity influences beta-cell functional capacity, with Asians having lower beta-cell regenerative capacity and insulin secretion compared to Caucasians, leading to T2DM at lower BMI levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →